Azacitidine Plus Venetoclax Is Not Cost-Effective for Some Patients With AML
Cost-effectiveness model was developed to compare costs and other factors of azacitidine/venetoclax combination with azacitidine alone in patients with AML.
Diagnosis & Disease Information
Next-Generation Approaches to Karyotyping in Acute Myeloid Leukemia
Researchers revisited the techniques traditionally used to assess CNAs and translocations in routine AML diagnostics to challenge the recommended CCA.
Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Flotetuzumab Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Researchers sought to find out if flotetuzumab shows activity with an acceptable safety profile in patients with acute myeloid leukemia and primary induction failure or early relapse.
Thymoglobulin as GVHD Prophylaxis in AML Conditioning Regimens
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
Fractionated Gemtuzumab Ozogamicin Not Linked With Increased VOD/SOS Risk in Acute Myeloid Leukemia
Among patients with de novo AML, fractionated-dose gemtuzumab ozogamicin does not appear to increase the risk of hepatic VOD/SOS after HSCT.
Analysis of the Prognostic Value of the Fibrinogen-Albumin Ratio Index
A new study evaluated the prognostic value of the Fibrinogen-Albumin Ratio Index in certain conditions.
Fractionated Busulfan Improves NRM and Survival in AML and MDS
Researchers compare fractionated busulfan myeloablative conditioning to traditional RIC in elderly patients undergoing allogeneic hematopoietic stem cell transplantation.
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...